



SESSION (3)

Biosimilars: Where are we now?

3.1 Interactive Case Presentation

3.2 State-of-the-Art Plenary: *How Should Canadian IBD Docs Be Using Biosimilars?*

3.3 Expert Panel Review/Q&A

1. Identify a question, idea or controversy you would like to answer or address:

2. Identify a stimulus for the above:

3. Define how you will approach the problem (resources or references):

4. Report the learning outcome(s). How will this impact your clinical practice, expertise or current knowledge base?

5. Record the number of hours: _____